Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Grant Support/Research Contract - Boehringer Ingelheim, Bristol Myers Squibb, Reprieve inc., Sequana Medical, Abbott, Merck
• Consultant Fee/Honoraria/Speaker's Bureau - Boehringer Ingelheim, Bristol Myers Squibb, Cardionomic, MagentaMed, Reprieve inc., FIRE1, Sequana Medical, Merck, Windtree Therapeutics, Precardia, Regeneron, BD, Edwards life sciences, and Lilly.
• Equity/Stock(s)/Options - Reprieve inc, Sequana medical